We participate in numerous events promoting our portfolio companies and meeting our clients.

2017

RhoVac AB, a Ventac portfolio company, reports that patient recruitment for the company’s on-going phase I/II study is now complete. The goal of the study is to evaluate the safety of RV001 vaccine and record potential immune responses in treated patients. For more information, please visit this link.

Idogen AB, a Ventac portfolio company, announced today that the company has been awarded funding of 2.9 million Euro from Horizon 2020, the EU Framework Programme for Research and Innovation, for the development of the company’s tolerogenic vaccine for the treatment of patients with severe hemophilia A and inhibitory antibodies against factor VIII. For more information, please visit this link.

Idogen AB, a Ventac portfolio company, announces allowance/grant of a patent application, covering the company’s tolerogenic vaccine technology in Japan, Europe and the US. For more information, please follow this link.

Ventac Partners invest in Neuroscience Technologies to acquire significant co-ownership, and has deployed its international team to the company to grow the business. Neuroscience Technologies is a global leader in human pain neurophysiology. Employing microneurography technology developed over the last decade, Neuroscience Technologies has successfully provided services to the pharmaceutical industry with pre-clinical and clinical services in neuropathic pain and other peripheral nervous disorders quantifying spontaneous activity in pain fibers. For more information on Neuroscience Technologies, visit www.nsc-tec.com.

Idogen AB, a Ventac portfolio company, announced that the European Commission has granted an orphan drug designation to Idogen’s treatment approach in patients with hemophilia. For more information, please follow this link.

RhoVac AB, a Ventac portfolio company, announced that the Danish Medicines Agency and the Ethics Committee issued their respective approvals to RhoVac’s application to initiate its first clinical study. The planned phase I / II trial will be an open study including approximately 20 patients diagnosed with metastatic cancer. For more information, please follow this link (in Swedish).

Subscribe to our Newsletter

Thank you!